It is interesting to note that TNFα, a cytokine that plays a central role in IBD pathogenesis [76] and is the target of IBD drugs [77], inhibits HNF4α activity through a pathway involving NFkB [78]. Here, NFKB1 is linked to irritable bowel syndrome.